An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Males and females, ≥ 18 years of age
• Diagnosis of mild to moderate asthma for at least 12 months
• Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
• Airway reversibility ≥ 12% and 200 mL improvement in FEV1
• Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
• Willing and able to comply with all study requirements and procedures
Locations
United States
Kansas
The University of Kansas Medical Center
RECRUITING
Kansas City
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Contact Information
Primary
Celldex Therapeutics
clinicaltrials@celldex.com
844-723-9363
Time Frame
Start Date: 2026-02
Estimated Completion Date: 2027-03
Participants
Target number of participants: 12
Treatments
Experimental: CDX-622
Eligible participants will receive a single dose
Related Therapeutic Areas
Sponsors
Leads: Celldex Therapeutics